Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Oncology

Understanding Your Pathology Report: Grades & Margins

At a Glance

Your sarcoma pathology report guides your treatment based on two main factors: the FNCLCC grade (how fast the tumor is growing) and the surgical margins (whether all cancer was removed). An R0 margin means the edges are clear, which is the goal of surgery.

Your pathology report is the most important document in your medical file. It is the roadmap your doctors will use to decide whether you need radiation, chemotherapy, or further surgery. While it may look like a wall of technical jargon, two key sections determine the “aggressiveness” of your cancer: the Grade and the Margin Status.

Decoding the FNCLCC Grade

The FNCLCC system (named after the French Federation of Cancer Centers) is the international standard for grading soft tissue sarcomas [1][2]. It assigns your tumor a grade from 1 to 3 based on three specific features [3]:

  1. Tumor Differentiation (Score 1-3): This measures how much the cancer cells look like normal cells. A score of 1 means they look very similar to healthy tissue; a score of 3 means they look wildly different or “undifferentiated” [1].
  2. Mitotic Count (Score 1-3): This counts how many cells are actively dividing (mitoses). More dividing cells mean the tumor is growing faster [2].
  3. Tumor Necrosis (Score 0-2): This measures “dead” areas within the tumor. Aggressive tumors often grow so fast they outpace their blood supply, causing parts of the tumor to die (necrosis) [1].

What the Grades Mean:

  • Grade 1 (Score 2–3): Low-grade. These tumors grow slowly and are less likely to spread (metastasize) to other parts of the body [1].
  • Grade 2 (Score 4–5): Intermediate-grade.
  • Grade 3 (Score 6–8): High-grade. These are the most aggressive tumors and require the most intensive treatment strategies [1][2].

Understanding Surgical Margins

When a surgeon removes a sarcoma, they aim to take a “cuff” of healthy tissue around it. The pathologist then “inks” the outside of that tissue and looks at it under a microscope to see how close the cancer cells get to the edge [4].

  • R0 (Negative Margin): No cancer cells are found at the very edge (the ink). This is the goal of every surgery [5].
  • R1 (Microscopic Positive): The tumor “touches the ink” under a microscope, even if the surgeon couldn’t see it with their eyes [4].
  • R2 (Macroscopic Positive): The surgeon could see that some tumor was left behind during the operation [4].

Planned vs. Unplanned Margins

It is critical to distinguish between a planned R1 and an unplanned R1.

  • A planned R1 occurs when a specialized surgeon intentionally leaves a microscopic amount of tumor to save a vital structure, like a major nerve or a blood vessel. This is anticipated and usually managed afterward with radiation [6].
  • An unplanned R1 often happens when a tumor is removed by a doctor who didn’t realize it was a sarcoma. These cases have a much higher risk of the cancer returning and often require a second, more extensive surgery [7][8].

Pathology Report Checklist

Every high-quality sarcoma pathology report should include these essential components [9][10]:

  • [ ] Histologic Subtype: (e.g., Leiomyosarcoma, Liposarcoma)
  • [ ] Tumor Size: Measured in centimeters (cm)
  • [ ] Tumor Depth: (e.g., above or below the muscle fascia)
  • [ ] FNCLCC Grade: Including the scores for differentiation, mitosis, and necrosis
  • [ ] Margin Status: R0, R1, or R2, including the distance in millimeters (mm)
  • [ ] Molecular Markers: Results from tests like FISH or NGS, if performed [11]

The Power of a Second Opinion

Because sarcomas are so rare and diverse, general pathologists may occasionally misclassify them [12]. Studies show that having your pathology reviewed by a specialized sarcoma pathologist at a high-volume center can lead to a change in diagnosis for many patients, directly impacting the treatment they receive [13][14]. If your biopsy was not performed at a dedicated sarcoma center, seeking a second opinion on the pathology is a standard and recommended step [12].

Common questions in this guide

What is the FNCLCC grading system for sarcomas?
The FNCLCC system is the international standard for grading soft tissue sarcomas from 1 to 3. It scores the tumor based on how normal the cells look, how fast they are dividing, and how much of the tumor is dead tissue.
What does a positive margin (R1 or R2) mean?
A positive margin means cancer cells were found at or near the edge of the removed tissue. An R1 margin means the cells were only seen under a microscope, while an R2 margin means visible tumor was left behind during surgery.
What is the difference between a planned and unplanned R1 margin?
A planned R1 margin happens when a specialized surgeon intentionally leaves microscopic cancer cells to save a vital structure like a nerve or blood vessel. An unplanned R1 usually occurs when a tumor is removed before doctors realize it is a sarcoma, which carries a higher risk of the cancer returning.
Should I get a second opinion on my sarcoma pathology report?
Yes, getting a second opinion from a specialized sarcoma pathologist is highly recommended. Because sarcomas are rare, having an expert at a high-volume center review your biopsy can ensure an accurate diagnosis and treatment plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does this pathology report use the FNCLCC grading system, and what were the specific scores for differentiation, mitosis, and necrosis?
  2. 2.What is the exact distance (in millimeters) from the tumor to the nearest margin?
  3. 3.If my margin was R1, was this 'planned' to save a nerve or vessel, or was it 'unplanned'?
  4. 4.Has this pathology been reviewed by a specialized sarcoma pathologist at a high-volume center?
  5. 5.Based on the grade and margin status, what is my specific risk for local recurrence?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Prognostic evaluation of the Ki-67 labeling system in histological grading of non-small round cell sarcoma: a supplementary analysis of a randomized controlled trial, JCOG1306.

    Sugita S, Tanaka K, Oda Y, et al.

    Japanese journal of clinical oncology 2024; (54(6)):675-680 doi:10.1093/jjco/hyae020.

    PMID: 38391203
  2. 2

    Leiomyosarcoma FNCLCC G3 pT2B of broad ligament adherent to right oviduct - case report with molecular profiling.

    Wincewicz A, Kowalik A, Zięba S, et al.

    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2016; (57(4)):1409-1414.

    PMID: 28174812
  3. 3

    Histopathological Spectrum of Soft-Tissue Tumors with Immunohistochemistry Correlation and FNCLCC grading: A North Indian Experience.

    Singh HP, Grover S, Garg B, Sood N

    Nigerian medical journal : journal of the Nigeria Medical Association 2017; (58(5)):149-155 doi:10.4103/nmj.NMJ_226_16.

    PMID: 31198267
  4. 4

    Primary treated versus referred trunk and extremities soft tissue sarcomas: comparative analysis of initial treatment impact on disease control.

    Nardi WS, Aragone L, Quildrian SD

    Ecancermedicalscience 2025; (19()):1933 doi:10.3332/ecancer.2025.1933.

    PMID: 40606956
  5. 5

    Impact of surgical margin on survival in extremity soft tissue sarcoma: A systematic review and meta-analysis.

    Jang WY, Kim HS, Han I

    Medicine 2021; (100(3)):e24124 doi:10.1097/MD.0000000000024124.

    PMID: 33546021
  6. 6

    UK guidelines for the management of soft tissue sarcomas.

    Hayes AJ, Nixon IF, Strauss DC, et al.

    British journal of cancer 2025; (132(1)):11-31 doi:10.1038/s41416-024-02674-y.

    PMID: 38734790
  7. 7

    Impact of unplanned resection and re-excision of a soft tissue sarcoma on prognosis.

    Muñoz Muñoz P, Bajawi Carretero M, González Barranquero A, et al.

    Cirugia espanola 2020; (98(5)):281-287 doi:10.1016/j.ciresp.2019.10.007.

    PMID: 31806234
  8. 8

    A Case Report of Malignant Mesenchymal Tumor Presenting As Anterior Thigh Swelling: A Diagnostic Challenge.

    Rey J, Shukla S, Acharya S, et al.

    Cureus 2024; (16(3)):e55669 doi:10.7759/cureus.55669.

    PMID: 38586762
  9. 9

    [Preoperative diagnostics and typing of abdominal soft tissue sarcomas].

    Kirchberg J, Blum SFU, Pablik J, et al.

    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 2022; (93(1)):5-15 doi:10.1007/s00104-021-01528-0.

    PMID: 34757436
  10. 10

    Evaluation of the factors affecting survival and local recurrence in thigh soft tissue sarcomas.

    Yıldırım S, Çiftdemir M, Ustabaşıoğlu FE, et al.

    Joint diseases and related surgery 2024; (35(1)):130-137.

    PMID: 38108174
  11. 11

    Diagnostic Immunohistochemistry for Soft Tissue and Bone Tumors: An Update.

    Schaefer IM, Hornick JL

    Advances in anatomic pathology 2018; (25(6)):400-412 doi:10.1097/PAP.0000000000000204.

    PMID: 30134255
  12. 12

    ASO Practice Guidelines Series: Multidisciplinary Management of Retroperitoneal Sarcomas.

    Sarre Lazcano C, Cardona K, Callegaro D

    Annals of surgical oncology 2025; (32(7)):5343-5355 doi:10.1245/s10434-025-17284-y.

    PMID: 40346412
  13. 13

    Heterogeneity of Soft Tissue Sarcomas and Its Implications in Targeted Therapy.

    Du XH, Wei H, Zhang P, et al.

    Frontiers in oncology 2020; (10()):564852 doi:10.3389/fonc.2020.564852.

    PMID: 33072594
  14. 14

    Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow.

    Sreenath ND, Singh K, Rastogi S, et al.

    JCO global oncology 2026; (12(3)):e2500440 doi:10.1200/GO-25-00440.

    PMID: 41812090

This page explains sarcoma pathology terminology for educational purposes only. Your oncologist and specialized sarcoma pathologist are the best sources for interpreting your specific report and guiding your care.

Get notified when new evidence is published on Soft tissue sarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.